Fudan University
- Country
- 🇨🇳China
- Ownership
- Private
- Established
- 1905-01-01
- Employees
- 1K
- Market Cap
- -
- Website
- http://www.fudan.edu.cn
Tislelizumab Plus GX Versus Tislelizumab Plus GP in the Treatment of R/M NPC
- Conditions
- Interventions
- First Posted Date
- 2023-12-20
- Last Posted Date
- 2024-01-17
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 266
- Registration Number
- NCT06177301
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China
DEBIRI Combined With Chemotherapy and Bevacizumab in the Treatment of Unresectable Colorectal Cancer Liver Metastases
- Conditions
- Interventions
- First Posted Date
- 2023-12-20
- Last Posted Date
- 2023-12-20
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 39
- Registration Number
- NCT06177288
- Locations
- 🇨🇳
Zhongshan hospital, Fudan university, Shanghai, China
Different Immunochemotherapies in Small B-cell Non-Hodgkin Lymphoma (iNHL)
- First Posted Date
- 2023-12-14
- Last Posted Date
- 2024-02-23
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 220
- Registration Number
- NCT06170216
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China
Comparison of Kimura Versus Warshaw Technique for Laparoscopic Spleen-Preserving Distal Pancreatectomy
- Conditions
- Interventions
- First Posted Date
- 2023-12-12
- Last Posted Date
- 2023-12-12
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 240
- Registration Number
- NCT06167421
A Prospective Study of Liquid Biopsy for Pancreatic Cancer Early Detection
- Conditions
- First Posted Date
- 2023-12-12
- Last Posted Date
- 2023-12-12
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 276
- Registration Number
- NCT06166147
- Locations
- 🇨🇳
Department of Hepato-Biliary-Pancreatic-Splenic Surgery, Shanghai General Hospital, Shanghai, Shanghai, China
🇨🇳Department of Pancreatic and Hepatobiliary Surgery, Fudan University Shanghai Cancer Center; Pancreatic Cancer Institute, Fudan University, Shanghai, Shanghai, China
🇨🇳Department of General Sugery, Huadong Hospital, Shanghai, Shanghai, China
Real World Patient-Reported Outcomes in Chinese Her2+ EBC Patients Receiving (Neo) Adjuvant Anti-Her2 Based Therapy
- Conditions
- First Posted Date
- 2023-12-08
- Last Posted Date
- 2023-12-08
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 600
- Registration Number
- NCT06161922
- Locations
- 🇨🇳
Keda Yu, Shanghai, China
A Study of Lymph Node Metastatic Pattern Based Incorporating Tumor Location, GGO Components and Size for Non-small Cell Lung Cancer
- Conditions
- First Posted Date
- 2023-12-08
- Last Posted Date
- 2023-12-13
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 7067
- Registration Number
- NCT06161935
A Study of PD-1 Inhibitors Combined With Fruquintinib and Chemotherapy in First-line Treatment of HER2-negative Advanced G/GEJ Cancer
- Conditions
- Interventions
- First Posted Date
- 2023-12-06
- Last Posted Date
- 2023-12-06
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 58
- Registration Number
- NCT06158919
- Locations
- 🇨🇳
Fudan University ShangHai Cancer Center, Shanghai, Shanghai, China
PD-1 Inhibitor Based Induction Chemotherapy Followed by De-escalation Protocols in OPSCC
- Conditions
- Interventions
- First Posted Date
- 2023-12-05
- Last Posted Date
- 2023-12-05
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 60
- Registration Number
- NCT06156891
- Locations
- 🇨🇳
Eye & ENT Hospital of Fudan University, Shanghai, Shanghai, China
PD-1 Inhibitor Plus Anti-EGFR Therapy And Radiotherapy in Locally Advanced NPC Resistant to Induction Chemotherapy
- Conditions
- Interventions
- First Posted Date
- 2023-12-05
- Last Posted Date
- 2023-12-05
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 41
- Registration Number
- NCT06156878
- Locations
- 🇨🇳
Eye & ENT Hospital of Fudan University, Shanghai, Shanghai, China